Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -0.52%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlights a strong initial launch of Vafseo with higher-than-expected revenue and broad market access. There is positive momentum in Medicare Advantage uptake and a solid financial position with sufficient cash runway. However, challenges include decreased Auryxia revenue, specialty pharmacy fulfillment issues, and increased net loss. Overall, the sentiment remains cautiously optimistic due to the strong Vafseo launch and regulatory progress.Company Guidance
During Akebia's Fourth Quarter 2024 Financial Results Call, the company provided guidance for the initial launch of Vafseo, its HIF-PH inhibitor for anemia due to chronic kidney disease. In the first seven weeks of prescribing, Akebia reported expected net product revenue between $10 million and $11 million for the first quarter of 2025, ahead of analyst estimates. The launch strategy includes securing commercial supply contracts with dialysis providers covering nearly 100% of U.S. dialysis patients, achieving broad access, and driving prescriber demand. Over 500 physicians prescribed Vafseo, averaging about eight prescriptions each, with the company emphasizing the importance of gaining both breadth and depth in prescribing. Additionally, a significant portion of early prescriptions, over 15%, were covered by payers other than Medicare fee-for-service, indicating early success in Medicare Advantage plan coverage. Akebia also plans to initiate the VALOR study for non-dialysis patients in the second half of 2025, following a meeting with the FDA to discuss the study protocol. The company remains focused on making Vafseo the standard-of-care and is optimistic about its financial outlook, with cash and cash equivalents of $51.9 million as of December 31, 2024.Strong Launch of Vafseo
In the first quarter of 2025, Akebia expects $10 million to $11 million in net product revenue from Vafseo, exceeding analyst estimates. Over 500 physicians have prescribed Vafseo, with an average of eight prescriptions each.
Extensive Market Access Achieved
Commercial supply contracts are in place with dialysis providers covering nearly 100% of U.S. dialysis patients. There's significant early physician and dialysis organization engagement.
Positive Uptake in Medicare Advantage
15% of Vafseo prescriptions are covered under Medicare Advantage plans, indicating successful contracting by dialysis organizations.
Financial Stability and Cash Position
Cash and cash equivalents were $51.9 million at year-end 2024, with additional $18.4 million raised post year-end. This, along with operational cash flow, is expected to fund operations for at least two years.
Encouraging Regulatory Engagement for VALOR Study
FDA shows willingness to discuss the protocol for the VALOR Phase 3 trial, which could lead to potential approval for non-dialysis patients.
---
AKBA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AKBA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $1.93 | $1.69 | -12.44% |
| Nov 07, 2024 | $2.00 | $1.86 | -7.00% |
| Aug 08, 2024 | $1.11 | $1.19 | +7.21% |
| May 09, 2024 | $1.40 | $1.33 | -5.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics (AKBA) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Akebia Therapeutics (AKBA) earnings time?
Akebia Therapeutics (AKBA) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBA EPS forecast?
AKBA EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---